Search

everythinglearnresearchcommunity

for

Search:↓

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

A user reported using a 1mm derma stamp, rosemary oil, and pumpkin seed oil for 2 months and noticed baby hair growth where there was none before. They are questioning if this is real growth or just miniaturized hair.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

SCUBE3 is a potential hair loss treatment that people are hopeful about. It may provide a solution without the side effects of finasteride.

Beard to scalp hair transplants can provide 12,000-15,000 grafts for coverage, with fast recovery time. However, beard hair may grow curly and not suitable for frontal areas.

Minoxidil is discussed for hair loss treatment. Cucumber and potato are mentioned for dark circles.

Pyrilutamide is being used effectively for hair loss with no side effects, and the user is seeking a cheaper bulk supplier. Users discuss the difficulty of finding affordable, trustworthy sources, with some suggesting potential suppliers.

The conversation is about the effectiveness of Breezula for hair loss, with skepticism expressed due to lack of scientific proof and mixed results from those using Breezula and RU58841. Some are waiting for clinical trial results before trying treatments like Breezula and SM04554.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

Ibrox1972 shared an 8.5-month update on their 2,689-graft hair transplant by Dr. Raghu Reddy in London, along with using oral finasteride, oral minoxidil, and microneedling. Users praised the natural-looking results and discussed the importance of choosing a skilled doctor.

The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.

A user discusses an Iranian hair loss treatment brought by their mom, questioning its effectiveness. Replies mention that Kopexil, an ingredient in the product, is different from Minoxidil and less tested.

The conversation humorously discusses hair loss treatments, mentioning multiple hair transplants, oral minoxidil, and dutasteride, but not Breezula. It also jokes about the high cost and mild effectiveness of certain treatments.

Hair loss treatments pyrilutamide and GT20029 discussed. Pyrilutamide approval in 2 years, GT20029 in 5-6+ years.

The conversation is about finding sources for topical anti-androgens like CB, pyrilutamide, fluridil, and aflatridol for hair loss treatment. The user is considering using CB powder from IndiaMart but is concerned about side effects from finasteride and minoxidil.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

A user shared their 12-month update after a 5,800-graft hair and beard transplant performed by Dr. Tulunay in Istanbul, using Sapphire FUE and DHI techniques. The user noted significant growth around months 8-9 and expressed satisfaction with the results.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

Clascoterone is suggested as an alternative for those who experience side effects from finasteride and dutasteride. It is not widely available yet, but some users are obtaining it from compounding pharmacies or suppliers like Echemi.